Navigation Links
Certican in Medical Technology

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...he prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003. certican is not approved for use in the US. Afinitor important safety infor...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

...he prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003. certican is not approved for use in the US(1). For more information on Afinitor...

RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

...he prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003. certican is not approved in the US. Disclaimer The foregoing release contai...

RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial

...he prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003. certican is not approved in the US. In addition to breast cancer, RAD001 is ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

...ilable in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003. RAD001 is being evaluated as a single agent or in combination with existing therapies for renal cell ca...

Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer

...ilable in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003. In addition to renal cell carcinoma (RCC), RAD001 is being evaluated as a single agent or in combination with ...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

...ilable in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the European Union in 2003. RAD001 is being studied in two large Phase III studies in advanced NETs (pancreatic NET and carcin...

RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer

...ilable in different dosage strengths under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003. In addition to renal cell carcinoma (RCC), RAD001 is being evaluated as a single agent or in combination with ...

Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments

...in the world. Everolimus is approved under the trade name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003 and is available in more than 60 countries. About Femara Femara(R) (letrozole tablets) is approved for the ad...

RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

...in the world. Everolimus is approved under the trade-name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. certican was first approved in the EU in 2003 and is available in more than 60 countries. Disclaimer The foregoing release contains forward-looking stateme...
Other Tags
(Date:2/28/2015)... BC (PRWEB) February 28, 2015 Mew ... recently announced that they now provide business consulting services ... such as corporate tax planning and succession planning. Company ... entrusted to experienced professionals. On top of this, complex ... to handle corporate accounting. As a result, Mew and ...
(Date:2/28/2015)... Bethesda, MD (PRWEB) February 28, 2015 ... annual conference in person, the Mesothelioma Applied Research ... taking place on Tuesday, March 3, starting at 9:30 ... and requires no registration. The broadcast can be accessed ... visiting http://www.curemeso.org/symposium . , The Symposium is a ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Dr. ... Central Coast area residents, recently announced a special offer ... It’s a treatment option for new and established patients ... 2015 with a bright, white smile, Dr. Patel and ... of $299, marked down from the regular price of ...
(Date:2/28/2015)... 2015 How would you describe ... There are all kinds of different leaders, each ... of the advantages and applications of different leadership ... a new product this spring called The Leadership ... connection between personality type, leadership, and success. The ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 Developers of ... release of a new overlay plugin for Final Cut Pro ... Studios. , “FCPX Overlay Chromatic gives users total control over ... Christina Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic ... an easy to use interface.” , FCPX Overlay Chromatic Grunge ...
Breaking Medicine News(10 mins):Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
Other Contents